RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).
Jordi Bruix
Consultant or Advisory Role - ArQule; Bayer; Biocompatibles; Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Roche
Honoraria - Bayer; Biocompatibles; Bristol-Myers Squibb; Novartis
Research Funding - ArQule; Bayer; Daiichi Sankyo
Richard S. Finn
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Onyx
Masatoshi Kudo
No relevant relationships to disclose
Josep M. Llovet
Consultant or Advisory Role - Bayer; BioSphere Medical; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; NanoString Technologies
Honoraria - Bayer; Bristol-Myers Squibb; Lilly; NanoString Technologies
Research Funding - Bayer; Boehringer Ingelheim
Shukui Qin
No relevant relationships to disclose
Marie-Aude Le Berre
Employment or Leadership Position - Bayer
Andrea Wagner
Employment or Leadership Position - Bayer
Ann-Lii Cheng
Consultant or Advisory Role - Boehringer Ingelheim Taiwan Ltd